Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New probiotic aims to soothe tummy troubles in overweight adults

NCT ID NCT07336615

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study is testing a new probiotic called CLB101TM in healthy but overweight adults who have digestive issues like bloating or stomach pain. The probiotic is designed to produce a natural substance called butyrate, which may help strengthen the gut lining and support immune health. The study will check if the probiotic is safe and if it improves gut symptoms compared to a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

85 people

The number who actually took part.

Started

Oct 2025

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18-65 years old, inclusive * Has self-reported moderate to severe gastrointestinal or digestive symptoms, such as abdominal pain, bloating, flatulence, constipation, or diarrhea. * Has a Gastrointestinal Symptom Rating Scale (GSRS) score between 4-7. * Has a Body Mass Index (BMI) \>27 but \<35.0 kg/m\^2. * Willingness to refrain from taking probiotics or prebiotics during the study period. * Interested in understanding more about their gut health and the use of probiotic products. * If taking any OTC or prescription medications for anxiety (e.g. magnesium, anticholinergics, Buspirone, Tricyclics, MAOIs,) or other class of medication for anxiety, must be on a stable dose for at least 4 weeks prior to randomization and throughout the course of the study. * If using any cannabis-containing products, must be on a stable dose regimen for at least 4 weeks prior to randomization and throughout the course of the study. * If using any nicotine-containing products, must be on a stable regimen for at least 4 weeks prior to randomization and throughout the course of the study. Willing to practice a reliable method of contraception for the duration of the study * In good general health at the time of screening (Investigator discretion). * Able to read and understand English. * Able to read, understand, and provide informed consent. * Able to use a personal smartphone device and download Chloe by People Science. * Able to receive shipment of the product at an address within the United States and use at-home refrigerator and/or freezer. * Able to complete study assessments including two stool sample collections, two blood sample collections, two intestinal permeability urine tests, and a food diary over the course of up to 12 weeks. Exclusion Criteria: * Participants that do not have a personal smartphone, internet access, or unwilling to download Chloe. * Participants who are currently on a carnivore diet, raw food diet, fruitarian, liquid diet (does not include vegans or vegetarians). * Participants receiving any investigational therapies or treatments within 30 days prior to randomization. * Participants currently taking or have taken antibiotics, probiotic, or prebiotic supplements within the past 4 weeks prior to randomization. * Participants using immunosuppressive medications, systemic steroids, antifungals, NSAIDs or other medications known to significantly impact gastrointestinal function or microbiota. * Participants with a clinical diagnosis of any gastrointestinal illness, including but not limited to: * Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis) * Gastroesophageal reflux disease (GERD) * Gastric or duodenal ulcers * Celiac disease * Diverticular disease * Chronic pancreatitis * Gastroparesis * Severe liver disease (e.g., cirrhosis, hepatitis, NAFLD acceptable) * Gallbladder disease (e.g., cholecystitis, cholelithiasis) * Gastrointestinal cancer (Colorectal, Intestinal, Stomach, Liver, Gallbladder) * Participants with a known or suspected gastrointestinal infection, such as: * Clostridium difficile infection * Helicobacter pylori infection * Parasitic infections (e.g., Giardia, Cryptosporidium) * Participants with a history of gastrointestinal surgery, excluding appendectomy and cholecystectomy. * Participants with a history of gastrointestinal bleeding or perforation. * Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder. * Currently pregnant, planning to become pregnant in the next 3 months, or breastfeeding * Any underlying medical conditions or comorbidities that may confound the assessment of digestive symptoms or the evaluation of the study outcomes. * Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes. * Known hypersensitivity or previous allergic reaction to probiotics, microcrystalline cellulose, vegetarian capsules, silica, or magnesium stearate. * Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator. * Consume more than 2 (two) alcoholic drinks per day. * Cannabis or nicotine use that is weekly or more frequent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastrointestinal are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • People Science

    Los Angeles, California, 90034, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.